Panageas KS - Search Results

1

Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 Pandemic.

Moskowitz CS, Panageas KS. Moskowitz CS, et al. Among authors: panageas ks. JAMA Oncol. 2020 Sep 1;6(9):1326-1327. doi: 10.1001/jamaoncol.2020.2370. JAMA Oncol. 2020. PMID: 32556067 No abstract available.

2

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Modi S, et al. Among authors: panageas ks. Cancer Invest. 2005;23(6):483-7. doi: 10.1080/07357900500201301. Cancer Invest. 2005. PMID: 16203655

3

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB. Shoushtari AN, et al. Among authors: panageas ks. JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391. JAMA Oncol. 2018. PMID: 28817755 Free PMC article. Clinical Trial.

4

Design considerations for early-phase clinical trials of immune-oncology agents.

Wages NA, Chiuzan C, Panageas KS. Wages NA, et al. Among authors: panageas ks. J Immunother Cancer. 2018 Aug 22;6(1):81. doi: 10.1186/s40425-018-0389-8. J Immunother Cancer. 2018. PMID: 30134959 Free PMC article.

5

Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology.

Lavery JA, Callahan MK, Panageas KS. Lavery JA, et al. Among authors: panageas ks. JCO Clin Cancer Inform. 2021 Jan;5:21-23. doi: 10.1200/CCI.20.00096. JCO Clin Cancer Inform. 2021. PMID: 33411618 Free PMC article. No abstract available.

6

Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial.

Mao JJ, Liou KT, Baser RE, Bao T, Panageas KS, Romero SAD, Li QS, Gallagher RM, Kantoff PW. Mao JJ, et al. Among authors: panageas ks. JAMA Oncol. 2021 May 1;7(5):720-727. doi: 10.1001/jamaoncol.2021.0310. JAMA Oncol. 2021. PMID: 33734288 Free PMC article. Clinical Trial.

7

Acupuncture for Cancer Survivors-Reply.

Mao JJ, Baser RE, Panageas KS. Mao JJ, et al. Among authors: panageas ks. JAMA Oncol. 2021 Sep 1;7(9):1400-1401. doi: 10.1001/jamaoncol.2021.2520. JAMA Oncol. 2021. PMID: 34323960 No abstract available.

8

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS; AACR Project GENIE Consortium. Brown S, et al. Among authors: panageas ks. JAMA Oncol. 2022 Feb 1;8(2):287-291. doi: 10.1001/jamaoncol.2021.5153. JAMA Oncol. 2022. PMID: 34734967 Free PMC article.

9

Clinicopathological features of and risk factors for multiple primary melanomas.

Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Ferrone CR, et al. Among authors: panageas ks. JAMA. 2005 Oct 5;294(13):1647-54. doi: 10.1001/jama.294.13.1647. JAMA. 2005. PMID: 16204664

10

Cancer screening among patients with advanced cancer.

Sima CS, Panageas KS, Schrag D. Sima CS, et al. Among authors: panageas ks. JAMA. 2010 Oct 13;304(14):1584-91. doi: 10.1001/jama.2010.1449. JAMA. 2010. PMID: 20940384 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page